Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent

Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD
Cells in the Treatment of Intermittent Claudication to South Korea

CHA Bio Will Conduct and Fund the Trial; PLX-PAD Cells Are the First
Placental-Derived Allogeneic Cells Approved for Importation Into South Korea

HAIFA, Israel, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that the South Korean Ministry of Food and Drug
Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA), has
approved Pluristem's Investigational New Drug (IND) Application to conduct a
Phase II study using PLX-PAD cells for the treatment of Intermittent
Claudication (IC), a subset of peripheral artery disease (PAD).

The IND approved by the MFDS mirrors INDs already approved by regulators in
the USA, Germany and Israel. South Korea will be the fourth country
participating in this multi-national trial involving the use of PLX-PAD in IC.
CHA Bio&Diostech Co., Ltd. (KOSDAQ:KS), Pluristem's South Korean partner, will
fund the trial and conduct it in its healthcare facilities.

"Pluristem's ability to extend our Phase II study of IC into South Korea is
important for several reasons," commented Zami Aberman, Pluristem's Chairman
and CEO. "Partnering with CHA Bio to conduct the clinical trial in their
hospitals will accelerate the enrollment and strengthen our relationship with
our South Korean partner. Additionally, Pluristem is proud of the fact that
our PLX-PAD cells are the first placental-derived allogeneic cells allowed to
be imported into South Korea. We at Pluristem believe this is a validation of
Pluristem's expertise in cell therapy in general and PLX potential cell
therapy in particular."

About the Study

Pluristem's Phase II study of IC is a randomized, placebo-controlled trial
that will evaluate the safety and efficacy of two courses of PLX-PAD cells
versus placebo, administered via intramuscular injections. The study protocol
targets enrollment of 150 patients with IC: Fontaine class IIb, Rutherford
category 2-3.

The primary efficacy end point of the trial is the change in the maximal
walking distance from baseline during an exercise treadmill test. Secondary
endpoints are hemodynamic and quality of life measurements. Safety parameters
are also being assessed.

About Intermittent Claudication

IC is a subset of PAD caused by atherosclerosis of the lower extremity
arteries. IC is characterized by muscle pain, such as aching, cramping,
numbness or a sense of fatigue classically in the calf muscle, which occurs
during exercise, such as walking, and is relieved by a period of rest. The
prevalence of IC in the United States alone is approximately 14 million
patients and representing a cost of approximately $2.5 billion annually to the
National Healthcare Bill (References: The SAGE Group and HCUP 2007 Inpatient
Data).

About CHA Bio&Diostech

CHA Bio&Diostech Co., Ltd. is a leading biopharmaceutical company
headquartered in South Korea; its R&D focuses on stem cells, cell
therapeutics, medical device, and new drug development. The company is a
member of CHA Health Systems Group, which is comprised of a medical
university, medical centers and hospitals located in the US and Korea with in
excess of two thousand beds under care, stem cell research centers, personal &
preventive medicine, and bio venture divisions. CHA Bio&Diostech has multiple
stem cell R&D pipelines in therapeutic areas including Stargardt's disease,
age-related macular disease, Parkinson's disease, Alzheimer disease, Cerebral
Palsy and glioblastoma in mid- to late-stages of development. With its
extensive experience and research infra structure, CHA Bio&Diostech has built
up multiple strategic relations with major research institutions in the fields
of stem cell research and infertility. For more information visit
www.chabio.com, the content of which is not part of this press release.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions, and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss the planned
IC trial in South Korea, or when discuss our belief that the fact that PLX
cells are the first placental-derived allogeneic cells allowed to be imported
into South Korea validates Pluristem's expertise in cell therapy in general
and PLX potential cell therapy in particular, we are using forward-looking
statements. These forward-looking statements and their implications are based
on the current expectations of the management of Pluristem only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; we may encounter delays or
obstacles in launching and/or successfully completing our clinical trials; our
products may not be approved by regulatory agencies, our technology may not be
validated as we progress further and our methods may not be accepted by the
scientific community; we may be unable to retain or attract key employees
whose knowledge is essential to the development of our products; unforeseen
scientific difficulties may develop with our process; our products may wind up
being more expensive than we anticipate; results in the laboratory may not
translate to equally good results in real surgical settings; results of
preclinical studies may not correlate with the results of human clinical
trials; our patents may not be sufficient; our products may harm recipients;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market share and pressure on
pricing resulting from competition, which could cause the actual results or
performance of Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo